��������

Dr. Patrick A. Baeuerle is the co-founder of six MPM oncology portfolio companies including Harpoon Therapeutics (NASDAQ: HARP), iOmx Therapeutics, Maverick Therapeutics, TCR² Therapeutics (NASDAQ: TCRR), Werewolf Therapeutics and Cullinan Oncology, where he is the CSO of Biologics. Patrick serves on the board of directors of iOmx and TCR² and is an investment committee member of the UBS Oncology Impact Fund (OIF), an oncology-only crossover fund (both private and public equities) managed by MPM.

Prior to joining MPM as an Executive Partner in 2015, Patrick served as Vice President of Research and General Manager of Amgen Research Munich GmbH and as CSO for Micromet, where he was responsible for the development of BiTE antibody Blincyto®, which was approved by the U.S. FDA in 2014 in less than three months as a therapy for relapsed/refractory acute lymphoblastic leukemia. He earlier headed small-molecule drug discovery at Tularik, a publicly traded biotechnology company acquired by Amgen. Prior to this, he was Professor and Chairman of Biochemistry and Molecular Biology at the Medical Faculty of Freiburg University, Germany, where he did groundbreaking research on transcription factor NF-kappaB.

Patrick is the recipient of Xconomy’s 2019 “X of the Year Award”, and the European Molecular Biology Laboratory’s 2019 Lennart Philipson Award in recognition of his many contributions to the development of cancer immunotherapies. To date, he has published 243 PubMed-listed papers that have been cited more than 75,000 times. He has a Hirsch index of 132 and was rated Germany’s most frequently cited biomedical scientist of the decade (1990-1999), and among the top 50 worldwide (1990 to 1997).

Patrick holds a Ph.D. in Biology from the University of Munich (LMU) and performed post-doctoral research with Dr. David Baltimore at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology. He is also an Honorary Professor of Immunology of the Medical Faculty of LMU in Munich, Germany.